InvestorsHub Logo
Post# of 252476
Next 10
Followers 75
Posts 4687
Boards Moderated 0
Alias Born 09/06/2003

Re: rkrw post# 86227

Friday, 11/13/2009 2:19:16 PM

Friday, November 13, 2009 2:19:16 PM

Post# of 252476
ZGEN -

Telapravir is setting the bar higher with 12+12 i.e. ifn market falls in half. Adding additional orals will aim for shorter courses of treatment.



So, ifn's double their price. What are the orals thinking of charging? My guess is ifn-L, if it proves still to be necessary, will easily charge more per patient than any individual oral because it is a fairly good bet that it is significantly superior to other ifns in both efficacy and SAE - i.e. it won't have the competition problem that the direct anti-virals do.

Everyone is gunning for all oral, no ifn.



And that is it's downside - competition. (Note also that I love group think. Really, not a joke. It is where the money is - e.g. I would very much have liked to have found a way to make money on the Crestor CRP trial since the odds were much much better than the group think among the specialists said)

Bristol bet is that it will never happen.



No, as my math showed, Bristol need only have estimated a 30% chance it would never happen.

A huge bolus of hcv patients will be gone by the time a Bristol gets to the market.



Maybe. My guess is that IFN-L gets to market within 18 months of the first triple oral therapy becoming the norm. And if IFN is still necessary they take the market very very quickly.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.